Bavarian Nordic A/S’s BVNRY phase 3 chikungunya virus vaccine (CHIKV VLP (PXVX0317) clinical trial has hit its primary endpoint in healthy adults ≥65 years of age.
In the 22 days after receiving a single intramuscular injection of the virus-like particle vaccine, 87% of the participants had neutralizing antibodies above the threshold for seroprotection, agreed with authorities.
82% of the participants passed the threshold by Day 15, demonstrating a fast onset of protection for the VLP-based CHIKV vaccine candidate.
CHIKV VLP was well-tolerated in this older adult population, with similar rates of adverse events observed between the active and placebo groups. The trial will continue for a 6-month follow-up for both safety and immunogenicity.
The company is competing with Valneva SE VALN. Most recently, Valneva announced that Phase 3 data for its single-shot chikungunya vaccine candidate, VLA1553, were published in The Lancet.
VLA1553 demonstrated a seroresponse rate of 98.9% in participants 28 days after receiving the single administration.
This immunogenicity profile was similar in both younger and older adults, and 96% of participants maintained seroresponse six months after vaccination.
VLA1553 was generally safe and equally well tolerated in younger and older adults.
Image and article originally from www.benzinga.com. Read the original article here.